These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 7820185)

  • 1. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
    Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
    Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF; Hough KL; Holder WD
    Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms.
    Funk J; Schmitz G; Failing K; Burkhardt E
    Cancer Immunol Immunother; 2005 Jan; 54(1):87-92. PubMed ID: 15693143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
    Iho S; Shau HY; Golub SH
    Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.
    Mie K; Shimada T; Akiyoshi H; Hayashi A; Ohashi F
    Vet Immunol Immunopathol; 2016 Sep; 177():58-63. PubMed ID: 27436446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
    Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
    Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
    Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
    J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.
    Hank JA; Weil-Hillman G; Surfus JE; Sosman JA; Sondel PM
    Cancer Immunol Immunother; 1990; 31(1):53-9. PubMed ID: 2306756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
    Kruse CA; Mitchell DH; Lillehei KO; Johnson SD; McCleary EL; Moore GE; Waldrop S; Mierau GW
    Cancer; 1989 Oct; 64(8):1629-37. PubMed ID: 2790675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
    Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
    J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.